Updated on | Jul 7, 2010 | (month date, year) |
---|---|---|
Updated by | Michael Katz | (name of the lister) |
Originator | BBB Inc. a CCC (since Jan 2012), AAA Pharm. Inc. |
(name change or M&A in Jan 2012, BBB is a daughter company of CCC, AAA is the original company) (Full name of the original company) |
Nationality of originator | USA | |
Web site | www.abcd.com/research/pipeline.htm | |
Partners for co-development, licensing, distribution | ||
Lab. code or Brand name | AB001 | |
API, raw material | ab (INN), ac (USAN), ad (BAN) | |
Product Type | New chemical entity | |
Action Mechanism | Histone deacetylase (HDAC) inhibitor | |
Features |
orphan in USA, Europe. Fast track in USA, Europe. Promising. the first FD treatment. A fist-in-class product. a peptide by using A Pharma’s SP®-technology. Fast acting, long duration, pH depend controlled-release formulation |
(Features, Strong points, Technology etc. within 5 phrases) |
Pharmaceutial Form | Oral tablet, sustained release | |
Unit dosage | mg/tablet or mg/ml | |
Posology | Once a day or two times a day | |
WHO ATC | A02B | |
Indication | Asthma Chronic obstacle pulmonary disease (COPD) |
(the first indication). (the second indication) |
Lates development stage | Phase III
Phase II |
(for the first indication). (for the second indication). |
Generic (bio-similar) developers |